Journal
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
Volume 63, Issue 1, Pages 96-100Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAI.0b013e318289545c
Keywords
HIV; stribild; cobicistat; phase 3 randomized trial; efficacy; safety
Categories
Funding
- Gilead Sciences
- Bristol-Myers Squibb
- Janssen Therapeutics
- GlaxoSmithKline
- Merck Laboratories
- Tibotec
- Abbott Laboratories
- Aeliron Scientific
- anssen Therapeutics
- Achillion Pharmaceuticals
- Avexa
- Boehringer Ingelheim
- Hoff mann LaRoche
- Idenix, Janssen
- Merck
- Pfizer
- Sangamo
- Taimed
- Tobira
- Vertex
- ViiV
- Janssen
- Janssen Therapeutics and Gilead Sciences
Ask authors/readers for more resources
We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF was noninferior to EFV/FTC/TDF (88% vs 84%, difference + 3.6%, 95% confidence interval: -1.6% to 8.8%). Virologic success (HIV-1 RNA <50 copies/mL) was maintained at week 96 (84% vs 82%, difference +2.7%, 95% CI: -2.9% to 8.3%). Discontinuation due to adverse events was low (5% vs 7%). Median changes in serum creatinine (mg/dL) at week 96 were similar to week 48. These results support the durable efficacy and long-term safety of EVG/COBI/FTC/TDF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available